Moderna Inc.
(MrNa.O) said on Wednesday expected to report data from the Covid-19 vaccine trial in children aged between 2 and 5 years in March.
“If data supports and subject to regulatory consultations, Moderna can continue with the submission of regulations for children aged 2-5 years after,” said the company.
Modern vaccines, based on the RNA Messenger platform, already have authorization in Europe, Britain, Australia and Canada for teenagers aged 12-17 years, and have sent applications for children in 6 to 11 years.
In the United States, this vaccine was authorized by feeding food and drugs as a two-dose primary regimen and a dose of booster for adults aged 18 years and over.
The company, however, has not received authorization from the regulator for the use of its vaccines in children.
Moderna expects Covid-19 vaccine test data for children aged 2-5 years in March
